Secondary analysis of 240 adolescents with advanced classic Hodgkin lymphoma in the phase 3 S1826 trial: nivolumab-AVD gave higher 3-year PFS than brentuximab vedotin-AVD (93% vs 82%; HR 0.37). Thyroid dysfunction occurred in 7% with N-AVD; neuropathy was commoner with BV-AVD.
Secondary analysisn = 240
Castellino et al. Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826